Activist Investor 13D, 13G Filings


This page shows a list of all the recent 13D/G filings made by Celgene Corp /de/. Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

DateForm Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2017‑12‑08 SC 13G/A ATRA / Atara Biotherapeutics, Inc. 1,154,540
2017‑12‑06 SC 13D/A CRSP / CRISPR Therapeutics AG 4,834,980 3,722,534 -23.01 9.1 -26.02
2017‑09‑25 SC 13D/A XLRN / Acceleron Pharma Inc. 5,411,866 6,157,458 13.78 13.87 -5.00
2017‑09‑01 SC 13G BGNE / BeiGene, Ltd. 32,746,416 5.6
2017‑06‑27 SC 13D/A ALQA / Alliqua, Inc. 8,321,471 9,025,194 8.46 18.8 -5.53
2017‑04‑13 SC 13D/A ALQA / Alliqua, Inc. 8,025,194 8,321,471 3.69 19.9 0.00
2017‑03‑29 SC 13D/A ALQA / Alliqua, Inc. 8,025,194 8,025,194 0.00 19.9 0.00
2017‑03‑16 SC 13D/A ALQA / Alliqua, Inc. 8,025,194 8,025,194 0.00 19.9 -10.36
2017‑03‑01 SC 13D/A ALQA / Alliqua, Inc. 8,025,194 22.2
2016‑10‑31 SC 13D CRSP / CRISPR Therapeutics AG 4,834,980 12.3
2016‑08‑24 SC 13G OMED / OncoMed Pharmaceuticals, Inc. 2,970,588 2,970,588 0.00 8.1 0.00
2016‑08‑23 SC 13G OMED / OncoMed Pharmaceuticals, Inc. 2,970,588 8.1
2016‑01‑11 SC 13D/A XLRN / Acceleron Pharma Inc. 4,025,194 5,411,866 34.45 14.6 -8.18
2015‑05‑04 SC 13D/A XLRN / Acceleron Pharma Inc. 4,025,194 15.9